文献速递临床试验与 GCP真实世界研究与卫生经济

助听犬对重度及极重度听力损失患者的随机对照试验:效果与成本效果

Hearing dogs for people with severe and profound hearing loss: a wait-list design randomised controlled trial investigating their effectiveness and cost-effectiveness.
PubMed 文献 · Trials · 2021-10-14

本研究为单中心随机对照试验,纳入165名首次申请助听犬者,1:1随机分为提前获得助听犬组(HD)与常规等待组(WL)。6个月后HD组心理健康显著优于WL组(调整均差2.53,95%CI 1.27-3.79,p<0.001),焦虑、抑郁、功能、恐惧/社交隔离及感知依赖亦改善;当前慈善全额资助模式下具成本效果,公共部门全额资助不具成本效果,部分补贴或可探索。

要点

  • 助听犬可短期改善重度/极重度听力损失者的心理健康与社交功能。
  • 公共部门全额资助助听犬不具成本效果,部分补贴值得探索。
  • 试验为等待列表设计,首要结局为获得助听犬后6个月心理健康。

核心结论

  • 助听犬在短期内对受助者多个生活领域有益。
  • 当前慈善全额承担费用的模式下,从公共部门视角看助听犬具成本效果。
  • 公共部门全额资助不具成本效果,部分补贴可能具成本效果。

研究设计与样本

  • 单中心、等待列表对照的随机对照试验。
  • 纳入165名首次申请助听犬的参与者,1:1随机分为HD组(n=83)和WL组(n=82)。
  • 首要分析纳入112名(67.9%)参与者,其中HD组55名、WL组57名。
  • 首要结局为获得助听犬后6个月(T1)的心理健康(短沃里克-爱丁堡心理健康量表)。
  • 成本效果分析采用健康与社会照护视角。

主要发现

  • T1时HD组心理健康显著高于WL组(调整均差2.53,95%CI 1.27-3.79,p<0.001)。
  • HD组在焦虑、抑郁、功能、恐惧/社交隔离及感知依赖方面亦显著改善。
  • HD组平均使用的法定健康与社会照护资源更少。

关键数值与推荐

  • 纳入标准:首次申请者;申请助听犬(而非该慈善机构提供的其他支持)。
  • 随机分组:1:1分为提前获得助听犬(HD)或常规申请时限内等待(WL)。
  • 首要结局测量时间点:获得助听犬后6个月(T1)。

临床怎么用

  • 助听犬可作为重度/极重度听力损失者的补充干预,短期改善心理健康与社交功能。
  • 公共资助决策需考虑成本效果:全额资助不具成本效果,部分补贴或可探索。

局限性

  • 单中心研究,外部推广性受限。
  • 首要分析仅纳入67.9%的随机参与者,存在缺失数据偏倚可能。
  • 结局评估时间为短期(6个月),长期效果未知。
  • 试验为回顾性注册(ISRCTN36452009,2019年1月28日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hearing loss increases the risk of poor outcomes across a range of life domains. Where hearing loss is severe or profound, audiological interventions and rehabilitation have limited impact. Hearing dogs offer an alternative, or additional, intervention. They live permanently with recipients, providing sound support and companionship. METHODS: A single-centre, randomised controlled trial (RCT) evaluated the impacts of a hearing dog on mental well-being, anxiety, depression, problems associated with hearing loss (responding to sounds, fearfulness/social isolation), and perceived dependency on others. Participants were applicants to the UK charity 'Hearing Dogs for Deaf People'. Eligibility criteria were as follows: first-time applicant; applying for a hearing dog (as opposed to other support provided by the charity). Participants were randomised 1:1 to the following: receive a hearing dog sooner than usual [HD], or within the usual application timeframe (wait-list [WL] comparator). The primary outcome was mental well-being (Short Warwick-Edinburgh Mental Well-Being Scale) 6 months (T1) after HD received a hearing dog. The cost-effectiveness analysis took a health and social care perspective. RESULTS: In total, 165 participants were randomised (HD n = 83, WL n = 82). A total of 112 (67.9%) were included in the primary analysis (HD n = 55, WL n = 57). At T1, mental well-being was significantly higher in the HD arm (adjusted mean difference 2.53, 95% CI 1.27 to 3.79, p < 0.001). Significant improvements in anxiety, depression, functioning, fearfulness/social isolation, and perceived dependency, favouring the HD arm, were also observed. On average, HD participants had used fewer statutory health and social care resources. In a scenario whereby costs of provision were borne by the public sector, hearing dogs do not appear to be value for money. If the public sector made a partial contribution, it is possible that hearing dogs would be cost-effective from a public sector perspective. CONCLUSIONS: Hearing dogs appear to benefit recipients across a number of life domains, at least in the short term. Within the current funding model (costs entirely borne by the charity), hearing dogs are cost-effective from the public sector perspective. Whilst it would not be cost-effective to fully fund the provision of hearing dogs by the public sector, a partial contribution could be explored. TRIAL REGISTRATION: The trial was retrospectively registered with the International Standard Randomised Controlled Trial Number (ISRCTN) registry on 28.1.2019: ISRCTN36452009 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Stuttard L, Boyle P, Fairhurst C, et al. Hearing dogs for people with severe and profound hearing loss: a wait-list design randomised controlled trial investigating their effectiveness and cost-effectiveness. Trials. 2021. PMID: 34649618. doi:10.1186/s13063-021-05607-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。